Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses.
暂无分享,去创建一个
T Stijnen | D E Grobbee | A. Hoes | D. Grobbee | T. Stijnen | J. Lubsen | D. Grobbee | L. Arends | A W Hoes | J Lubsen | L R Arends | T. Stijnen
[1] N J Nagelkerke,et al. Variation in baseline risk as an explanation of heterogeneity in meta-analysis by S. D. Walter, Statistics in Medicine, 16, 2883-2900 (1997) , 1999, Statistics in medicine.
[2] P. Flandre,et al. Estimating the proportion of treatment effect explained by a surrogate marker by D. Y. Lin, T. R. Fleming and V. De Gruttola, Statistics in Medicine, 16, 1515–1527 (1997) , 1999 .
[3] H. V. van Houwelingen,et al. Investigating underlying risk as a source of heterogeneity in meta-analysis. , 1999, Statistics in medicine.
[4] S D Walter,et al. Variation in baseline risk as an explanation of heterogeneity in meta-analysis. , 1997, Statistics in medicine.
[5] S G Thompson,et al. Investigating underlying risk as a source of heterogeneity in meta-analysis. , 1997, Statistics in medicine.
[6] Daniel T. Larose,et al. Grouped random effects models for Bayesian meta-analysis. , 1997, Statistics in medicine.
[7] R J Cook,et al. A logistic model for trend in 2 x 2 x kappa tables with applications to meta-analyses. , 1997, Biometrics.
[8] Douglas G Altman,et al. The relation between treatment benefit and underlying risk in meta-analysis , 1996, BMJ.
[9] M. McIntosh,et al. The population risk as an explanatory variable in research synthesis of clinical trials. , 1996, Statistics in medicine.
[10] D J Spiegelhalter,et al. Bayesian approaches to random-effects meta-analysis: a comparative study. , 1995, Statistics in medicine.
[11] M. Egger,et al. Risks and benefits of treating mild hypertension: a misleading meta-analysis? , 1995, Journal of hypertension.
[12] D E Grobbee,et al. Does drug treatment improve survival? Reconciling the trials in mild‐to-moderate hypertension , 1995, Journal of hypertension.
[13] P. Rothwell,et al. Can overall results of clinical trials be applied to all patients? , 1995, The Lancet.
[14] A. Hoes,et al. Meta-analysis and the Hippocratic principle of primum non nocere--authors' reply. , 1995, Journal of hypertension.
[15] S G Thompson,et al. Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated , 1994, BMJ.
[16] R. Carroll,et al. Measurement error, instrumental variables and corrections for attenuation with applications to meta-analyses. , 1994, Statistics in medicine.
[17] S. Senn,et al. IMPORTANCE OF TRENDS IN THE INTERPRETATION OF AN OVERALL ODDS RATIO IN THEMETA-ANALYSIS OF CLINICAL TRIALS. AUTHOR'S REPLY , 1994 .
[18] H C Van Houwelingen,et al. A bivariate approach to meta-analysis. , 1993, Statistics in medicine.
[19] J. Collet,et al. An Effect Model for the Assessment of Drug Benefit: Example of Antiarrhythmic Drugs in Postmyocardial Infarction Patients , 1993, Journal of cardiovascular pharmacology.
[20] F. Song,et al. Cholesterol lowering and mortality: the importance of considering initial level of risk. , 1993, BMJ.
[21] F. Mosteller,et al. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. , 1992, JAMA.
[22] H Kragt,et al. Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. , 1992, Statistics in medicine.
[23] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.
[24] K A L'Abbé,et al. Meta-analysis in clinical research. , 1987, Annals of internal medicine.
[25] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.